OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Immunosenescence in Aging

Submission Deadline: March 30, 2022 (Open) Submit Now

Guest Editor

Gregory M. Fahy, PhD

Chief Scientific Officer, Intervene Immune Inc, Torrance, CA 90502 USA

Website | E-Mail

Research interests: Aging interventions; reversal of immunosenescence; reversal of epigenetic aging; cryopreservation

About This Topic

This special issue of OBM Geriatrics focuses on and addresses a particularly strategic, although complex, aspect of aging: immunological aging, or immunosenescence. The fact that immunological dysfunction predicts mortality in the elderly was established in 1974. For most, however, the impact of immunosenescence was brought home just last year by the more than 80-fold higher death rate from Sars-CoV-2 infection in those over 75 vs those under 20. Of the 6% of all deaths that are attributable to infectious disease, around 90% occur after the age of 60. But the problem is actually far worse, since we must also add to this toll a significant fraction of total cancer morbidity and mortality, given increasingly strong links between cancer risk and immune senescence. These grim facts, however, are increasingly being balanced by the good news, exemplified in this special issue, that intervention is now increasingly possible. The last decade, for example, saw the development of blockbuster drugs that are now extending the lives of cancer victims by blocking aspects of immune senescence. Future interventions will be much more powerful, preventing and even reversing aspects of or even the entirety of immunosenescence through a variety of complementary techniques. The future is promising, and this issue is intended to provide geriatricians with new insights, tools, and leads for intervening now and in the near future. May your patients thank you for what you learn here!

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!